Consultation process with Swedish unions completed
LUND (SWEDEN) – Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company that has launched the world’s first test dedicated to the early detection of pancreatic cancer, today announced that the consultation process regarding realigning its Swedish operations, announced on 19 January 2023, has been completed.
Immunovia is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray™ PanCan-d test. Following the early experience from the research collaboration with Proteomedix that was initiated in October 2022, Immunovia determined that the company’s in-house need for R&D capability has changed and initiated a union consultation process with the aim to reduce the number of employees within R&D and Operations in Lund.
The consultation process with unions has now been completed and the related financial impact is approximately SEK 10 million reduced operational costs on an annual basis.
For more information, please contact:
Philipp Mathieu,
CEO and President
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
About Immunovia
Immunovia is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available for early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.